Prosecution Insights
Last updated: September 17, 2026
Application No. 18/032,930

SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Non-Final OA §112
Filed
Oct 23, 2023
Priority
Oct 20, 2020 — CN 202011128302.9 +3 more
Examiner
WEDDINGTON, KEVIN E
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Zelgen Pharma Tech Co. Ltd.
OA Round
2 (Non-Final)
75%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1104 granted / 1469 resolved
+15.2% vs TC avg
Moderate +10% lift
Without
With
+10.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
48 currently pending
Career history
1492
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
28.3%
-11.7% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
28.6%
-11.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1469 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1 and 3-14 are presented for examination. Applicants’ amendment and response filed July 28, 2026 have been received and entered. Accordingly, the rejection made under 35 USC 102(a)(2) as being anticipated by WO 2018/115380 A1, hereby known as Gmachl et al. as set forth in the previous Office action dated April 28, 2026 at pages 2-4 as applied to claim 1 is hereby WITHDRAWN due to applicants’ amendment to claim 1 to incorporate the limitations of claim 2. Claims 12-14 are withdrawn from consideration as being drawn to the non-elected invention (37 CFR 1.142(b)). Applicants request for rejoinder is deemed persuasive, therefore, non-elected claims 12-14 will be rejoined. Allowable Subject Matter Claims 1, 3-11 and 13 are allowable. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 14 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a Written Description rejection. A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species); In re Ruschig, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967). An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics. In particular, the specification as original filed fails to provide sufficient written bases of any of the agents demonstrating wherein possession of use of the broad term: a disease associated with the activity or expression level of SOS1. The mere fact that Applicant may have discovered one type of disease associated with the activity or expression of SOS1 with the administration of a substituted benzo- or pyrido-pyrimidinamine compound having a structure of general formula (III) is not sufficient to claim the entire genus. The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]." Claim 14 is not allowed. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 12 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 12 is rendered indefinite because the claim recites the preparation for formula (I), which was deleted in claim 1. Note in claim 12, lines 6 and 12, shows deleted formula I. Also note in claim 12, line 15, formula III does not have a R4 substituent. Claim 12 is not allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN E WEDDINGTON whose telephone number is (571)272-0587. The examiner can normally be reached M-F 1:30-10:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeff Lundgren can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. KEVIN E. WEDDINGTON Primary Examiner Art Unit 1629 /KEVIN E WEDDINGTON/Primary Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Oct 23, 2023
Application Filed
Apr 28, 2026
Non-Final Rejection mailed — §112
Jul 28, 2026
Response Filed
Aug 17, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734159
METHODS OF TREATING SPINAL CORD INJURY OR DAMAGE
3y 0m to grant Granted Sep 15, 2026
Patent 12714688
MARGARIC ACID DECREASES PIEZ02-MEDIATED PAIN
4y 0m to grant Granted Aug 25, 2026
Patent 12702654
COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA AND OTHER CONDITIONS USING POLYAMINES
3y 3m to grant Granted Aug 11, 2026
Patent 12691123
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
3y 7m to grant Granted Jul 28, 2026
Patent 12691121
TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
3y 2m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
75%
Grant Probability
85%
With Interview (+10.2%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1469 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month